Tradestie Institutional Equity Comparison Engine
CVM vs TARS โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CVM Overall Edge
CVM Captures Institutional Edge (2โ2 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Cel-Sci Corporation (CVM) driven by superior Valuation, Growth & Margin while TARS counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, CVM trades at 23.0x Forward P/E with 0.0% operating margin (-62.7% YoY revenue) versus TARS at 63.7x Forward P/E and -9.6% operating margin (+63.9% YoY). In options structure, CVM sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against TARS sits in CONSOLIDATION (4th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
CVM
CVM 23.0x vs TARS 63.7x Fwd P/E
Growth & Margin Winner
CVM
Op Margin 0.0% vs -9.6% ยท YoY -62.7% vs +63.9%
Momentum & Technical Winner
TARS
1Y -77.5% vs +7.3% ยท 52W Pos 10% vs 64%
Options & Structure Winner
TARS
BREAKDOWN (N/A IV) vs CONSOLIDATION (4th %ile IV)
CVM
NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.59
+24.22% 1D
Market Cap
$20.9M
1M Return
-11.17%
1Y Return
-77.48%
Forward P/E
23.0x
Unified AI Score
56.6 / 100
HOLD
Tech 60.0
Fund 54.0
Flow 50.0
Mom 60.0
TARS
NASDAQ
Tarsus Pharmaceuticals, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$77.83
-3.06% 1D
Market Cap
$3.8B
1M Return
+14.33%
1Y Return
+7.3%
Forward P/E
63.7x
Unified AI Score
39.5 / 100
SELL
Tech 15.0
Fund 44.0
Flow 68.0
Mom 54.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CVM -77.48%
TARS +7.3%
Spread: +82.71 pp (TARS Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CVM Revenue | TARS Revenue | CVM Op. Margin | TARS Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2012 | $0M | N/A | -6772.3% | N/A | CVM |
| FY2013 | $0M | N/A | -12450.1% | N/A | CVM |
| FY2014 | $0M | N/A | -9721.4% | N/A | CVM |
| FY2021 | N/A | $60M | N/A | -21.3% | TARS |
| FY2022 | N/A | $30M | N/A | -242.9% | TARS |
| FY2023 | N/A | $20M | N/A | -820.5% | TARS |
| FY2024 | N/A | $180M | N/A | -65.9% | TARS |
| FY2025 | N/A | $450M | N/A | -15.7% | TARS |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CVM | TARS | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $20.9M | $3.8B | Larger Scale | TARS |
| Trailing P/E Ratio Valuation | 23.0x | 63.7x | Lower Multiple | CVM |
| Forward P/E Ratio Valuation | 23.0x | 63.7x | Lower Multiple | CVM |
| Revenue Growth (YoY) Growth | -62.7% | +63.9% | Higher Growth | TARS |
| Operating Margin (TTM) Profitability | 0.0% | -9.6% | Higher Margin | CVM |
| Net Profit Margin Profitability | 0.0% | -102.9% | Higher Margin | CVM |
| Return on Equity (ROE) Capital Efficiency | -252.5% | -319.8% | Higher ROE | CVM |
| 52-Week Range Position Momentum | 10% ($1โ$8) | 64% ($54โ$92) | Stronger Trend | TARS |
| Beta / 30D Volatility Risk Regime | 0.65ฮฒ ยท 120% Vol | 0.53ฮฒ ยท 45% Vol | Lower Realized Risk | TARS |
| Unified Institutional Score Composite Signal | 56.6 / 100 (HOLD) | 39.5 / 100 (SELL) | Higher Composite | CVM |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CVM vs TARS Buy Guide
CVM
BREAKDOWN
29d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
TARS
CONSOLIDATION
50d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
4th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CVM nor TARS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.